Your browser doesn't support javascript.
loading
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
Hughes, T P; Leber, B; Cervantes, F; Spector, N; Pasquini, R; Clementino, N C D; Schwarer, A P; Dorlhiac-Llacer, P E; Mahon, F-X; Rea, D; Guerci-Bresler, A; Kamel-Reid, S; Bendit, I; Acharya, S; Glynos, T; Dalal, D; Branford, S; Lipton, J H.
Afiliación
  • Hughes TP; Division of Haematology, SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
  • Leber B; Clinical Pathology, McMaster University, Hamilton, Ontario, Canada.
  • Cervantes F; Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Spector N; Departamento de Clínica Médica/FM, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Pasquini R; Division of Hematology and Medical Oncology, Federal University of Paraná, Curitiba, Brazil.
  • Clementino NCD; Hospital Das Clinicas da UFMG, Belo Horizonte, Brazil.
  • Schwarer AP; Department of Hematology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Dorlhiac-Llacer PE; Department of Hematology, Hospital das Clinicas FMUSP, São Paulo, Brazil.
  • Mahon FX; Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France.
  • Rea D; Unité de Thérapie Cellulaire et Clinique Transfusionnelle, Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France.
  • Guerci-Bresler A; Department of Hematology, Brabois Hospital, Vandoeuvre-lès-Nancy, Vandoeuvre, France.
  • Kamel-Reid S; Clinical Laboratory Genetics, Genome Diagnostics, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
  • Bendit I; Hematology Unit, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
  • Acharya S; Novartis Healthcare Pvt Ltd, Hyderabad, India.
  • Glynos T; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Dalal D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Branford S; Leukaemia Unit, Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide, Adelaide, South Australia, Australia.
  • Lipton JH; Blood and Marrow Transplant Service, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Leukemia ; 31(11): 2529-2531, 2017 11.
Article en En | MEDLINE | ID: mdl-28862704
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Leucemia Mielógena Crónica BCR-ABL Positiva / Proteínas de Fusión bcr-abl / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Leucemia Mielógena Crónica BCR-ABL Positiva / Proteínas de Fusión bcr-abl / Inhibidores de Proteínas Quinasas / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido